NOXXON Pharma AG to Initiate Phase Ib Clinical Trial of MCP-1 Inhibitor NOX-E36
BERLIN--(BUSINESS WIRE)--NOXXON Pharma AG announced today that it has permission to commence a multiple ascending dose study of its Monocyte Chemoattractant Protein-1 (MCP-1) targeting anti-inflammatory Spiegelmer®, NOX-E36. NOXXON plans to develop NOX-E36 for the treatment of diabetic nephropathy and other diabetes related complications.